Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY BERMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1578556098
CMS profile
1148570
Location
WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,716.38

215 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,043.90 206
Education $389.75 6
Long term medical supply or device loan $282.73 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $532.81 25
Seagen Inc. $327.81 14
Celgene Corporation $250.70 17
Merck Sharp & Dohme LLC $244.21 11
Sirtex Medical Inc $214.84 3
Astellas Pharma US Inc $183.68 5
AstraZeneca Pharmaceuticals LP $162.78 7
Janssen Biotech, Inc. $160.17 9
Genentech USA, Inc. $148.99 11
Exelixis Inc. $146.27 5
E.R. Squibb & Sons, L.L.C. $145.28 10
GENZYME CORPORATION $141.94 7
Takeda Pharmaceuticals U.S.A., Inc. $137.47 8
PFIZER INC. $134.73 5
Intuitive Surgical, Inc. $131.40 1
GlaxoSmithKline, LLC. $131.01 9
Daiichi Sankyo Inc. $105.88 4
SOBI, INC $103.06 5
Incyte Corporation $84.79 3
Rigel Pharmaceuticals, Inc. $82.71 3
THD America, Inc. $73.42 1
Shield Therapeutics Inc $69.56 3
Mirati Therapeutics, Inc. $67.87 3
Amgen Inc. $67.79 4
EMD Serono, Inc. $66.44 3
Pharmacyclics LLC, An AbbVie Company $64.21 3
AbbVie Inc. $63.69 3
AVEO Pharmaceuticals, Inc. $58.13 2
BeiGene USA, Inc. $55.80 3
ARRAY BIOPHARMA INC $52.92 3
Bayer Healthcare Pharmaceuticals Inc. $52.01 2
TerSera Therapeutics LLC $50.92 2
CTI BioPharma Corp. $40.85 2
Stemline Therapeutics Inc. $40.07 2
Alexion Pharmaceuticals, Inc. $36.18 2
Regeneron Healthcare Solutions, Inc. $30.21 1
Ipsen Biopharmaceuticals, Inc $24.71 1
Lilly USA, LLC $21.80 1
Pharmacosmos Therapeutics Inc. $21.56 1
Deciphera Pharmaceuticals Inc. $21.40 1
PharmaEssentia USA Corporation $19.26 1
Gilead Sciences, Inc. $19.21 1
Puma Biotechnology, Inc. $18.90 1
Eisai Inc. $18.53 1
Kite Pharma, Inc. $17.60 1
Kyowa Kirin, Inc. $16.88 1
Genmab U.S., Inc. $15.01 1
Agios Pharmaceuticals, Inc. $14.83 1
Foundation Medicine, Inc. $13.21 1
JAZZ PHARMACEUTICALS INC. $12.88 1

Page 2 of 5; records 51–100 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY BERMAN

NPI 1578556098 · CMS profile ID 1148570

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578556098?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY BERMAN, NPI 1578556098, CMS profile ID 1148570. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578556098?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BARRY BERMAN, NPI 1578556098, CMS profile ID 1148570. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578556098?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BARRY BERMAN, NPI 1578556098, CMS profile ID 1148570, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578556098?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

215 matching records · $4,716.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 215 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 215.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $26.1409/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003261981 CMS
Novartis Pharmaceuticals Corporation $11.2609/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726883 CMS
Janssen Biotech, Inc. $27.6109/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988278233 CMS
Pharmacyclics LLC, An AbbVie Company $30.3209/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998282077 CMS
GENZYME CORPORATION $6.8809/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049675779 CMS
Regeneron Healthcare Solutions, Inc. $30.2109/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999094559 CMS
Incyte Corporation $28.0909/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044409765 CMS
Seagen Inc. $19.5109/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995690745 CMS
Celgene Corporation $26.3709/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015319785 CMS
Incyte Corporation $27.7708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044409753 CMS
Novartis Pharmaceuticals Corporation $13.9508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726881 CMS
SOBI, INC $29.8308/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038119215 CMS
Astellas Pharma US Inc $23.7208/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034449313 CMS
E.R. Squibb & Sons, L.L.C. $15.7008/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015319721 CMS
Amgen Inc. $20.4608/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019828517 CMS
Novartis Pharmaceuticals Corporation $17.2308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726877 CMS
GENZYME CORPORATION $28.0208/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049675761 CMS
Shield Therapeutics Inc $22.9408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045804559 CMS
CTI BioPharma Corp. $22.9308/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039688405 CMS
Daiichi Sankyo Inc. $25.6508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006438253 CMS
PFIZER INC. $28.9708/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049883541 CMS
Merck Sharp & Dohme LLC $29.3008/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048672005 CMS
E.R. Squibb & Sons, L.L.C. $17.4307/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015319649 CMS
EMD Serono, Inc. $22.1707/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032315409 CMS
Genentech USA, Inc. $6.1007/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040309315 CMS
Seagen Inc. $13.0607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995690689 CMS
Janssen Biotech, Inc. $28.9807/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988278223 CMS
Intuitive Surgical, Inc. $131.4007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055577321 CMS
Mirati Therapeutics, Inc. $28.1707/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057986615 CMS
PFIZER INC. $21.5907/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049282389 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.8007/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055348701 CMS
Genmab U.S., Inc. $15.0107/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051342723 CMS
Novartis Pharmaceuticals Corporation $15.2007/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726873 CMS
Novartis Pharmaceuticals Corporation $21.2607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726865 CMS
Novartis Pharmaceuticals Corporation $0.4507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726869 CMS
SOBI, INC $26.0607/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038111001 CMS
Seagen Inc. $7.1107/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995690711 CMS
Novartis Pharmaceuticals Corporation $0.4107/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726853 CMS
Novartis Pharmaceuticals Corporation $13.5307/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991726857 CMS
Rigel Pharmaceuticals, Inc. $26.1007/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033408855 CMS
Celgene Corporation $22.5307/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015319675 CMS
Celgene Corporation $0.3307/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015319683 CMS
Janssen Biotech, Inc. $17.8607/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988278271 CMS
AbbVie Inc. $20.4106/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996243813 CMS
PFIZER INC. $30.5306/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049350921 CMS
GlaxoSmithKline, LLC. $17.8106/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003259747 CMS
Genentech USA, Inc. $24.6106/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040309285 CMS
Astellas Pharma US Inc $17.2606/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034220285 CMS
Merck Sharp & Dohme LLC $28.2406/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048671991 CMS
Merck Sharp & Dohme LLC $28.4206/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048671685 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,679.87 102
PY2020 $6,561.71 117
PY2021 $4,013.03 127
PY2022 $3,730.07 179
PY2023 $4,716.38 215
PY2024 $4,490.61 221
PY2025 $6,560.13 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $308,081.78 43
PY2024 Principal investigator $340,319.45 31
PY2023 Principal investigator $477,833.96 84
PY2022 Principal investigator $101,058.43 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738955
Principal investigator 1 Genentech, Inc. $2,800.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649995
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738953
Principal investigator 1 Genentech, Inc. $2,800.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649921
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738951
Principal investigator 1 Aadi Bioscience, Inc. $100.00 10/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946897
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,750.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185537459
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738921
Principal investigator 1 SEAGEN INC. $3,000.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228821061
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738923
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,900.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738925
Principal investigator 1 SEAGEN INC. $3,000.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228821034
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738927
Principal investigator 1 Genentech, Inc. $36,950.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649853
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738929
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,600.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185537475
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,150.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185537463
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738931
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738933
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738935
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738937
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,385.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185537473
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,334.25 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537465
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,750.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185537467
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,266.26 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537471
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738939
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738941
Principal investigator 1 Mirati Therapeutics, Inc. $2,379.00 04/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530690
Principal investigator 1 SEAGEN INC. $3,000.00 04/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA No dispute reported 06/30/2026 1228821594
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,125.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738943
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738945
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $450.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738947
Principal investigator 1 SEAGEN INC. $3,000.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228822386
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,450.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185537461
Principal investigator 1 Mirati Therapeutics, Inc. $7,568.62 03/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530698
Principal investigator 1 Aadi Bioscience, Inc. $3,066.36 03/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946895
Principal investigator 1 Aadi Bioscience, Inc. $3,000.00 02/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181946893
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233738949
Principal investigator 1 SEAGEN INC. $3,000.00 01/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228821919
Principal investigator 1 Amgen Inc. $19,207.29 01/27/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS - EAST
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246641391
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,700.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537469
Principal investigator 1 Mirati Therapeutics, Inc. $30,000.00 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530694
Principal investigator 1 SEAGEN INC. $3,000.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228822369